<DOC>
	<DOCNO>NCT00276757</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth Langerhans cell histiocytosis , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may effective treatment Langerhans cell histiocytosis . PURPOSE : This randomized clinical trial study combination chemotherapy see well work treat young patient Langerhans cell histiocytosis .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Young Patients With Langerhans Cell Histiocytosis</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy , term response initial therapy , prednisolone , vinblastine , mercaptopurine v without methotrexate leucovorin calcium young patient Langerhans cell histiocytosis . - Compare progression-free survival patient low-risk Langerhans cell histiocytosis respond initial therapy treat 6-month vs 12-month continuation therapy comprise prednisolone vinblastine . Secondary - Compare acute long-term toxicity incidence permanent effect . - Compare overall progression-free survival , response rate , time response . OUTLINE : This randomize , multicenter study one pilot nonrandomized stratum . Patients stratify accord number system involve ( multiple v single ) organ involve ( risk vs low risk ) . - Stratum 1 ( risk patient ) : Patients stratify accord participate center . Patients randomize 1 2 treatment arm ( arm I II ) . - Arm I : - Initial therapy : Patients receive oral prednisolone 3 time daily day 1-28 followed taper day 29-42 vinblastine IV day 1 , 8 , 15 , 22 , 29 , 36 . Patients achieve nonactive disease ( NAD ) course 1 proceed continuation therapy . Patients achieve intermediate response disease regression receive second course* initial therapy . Patients achieve NAD disease regression course 2 proceed continuation therapy . - Continuation therapy : Patients receive oral mercaptopurine daily 3 week , pulse oral prednisolone 3 time daily day 1-5 , vinblastine IV day 1 . Treatment repeat every 3 week day 365 begin therapy absence disease progression unacceptable toxicity . - Arm II : - Initial therapy : Patients receive prednisone vinblastine arm I initial therapy . Patients also receive methotrexate IV 24 hour day 1 , 15 , 29 oral leucovorin calcium twice daily day 2,16 , 30 . Patients achieve NAD course 1 proceed continuation therapy . Patients achieve intermediate response disease regression receive second course* initial therapy . Patients achieve NAD disease regression course 2 proceed continuation therapy . - Continuation therapy : Patients receive oral mercaptopurine daily 3 week , pulse oral prednisolone 3 time daily day 1-5 , vinblastine IV day 1 , oral methotrexate day 1 . Treatment repeat every 3 week day 365 begin therapy absence disease progression unacceptable toxicity . - Stratum 2 ( low-risk patient ) : Patients stratify accord age diagnosis ( â‰¤ 2 v &gt; 2 ) participate center . Patients randomize 1 2 treatment arm ( arm III IV ) first course initial therapy . - Arm III : - Initial therapy : Patients receive prednisolone vinblastine course 1 stratum 1 arm I initial therapy . Patients achieve NAD disease regression course 1 proceed continuation therapy . Patients achieve intermediate bad response receive second course* initial therapy . Patients achieve NAD , disease regression , intermediate response course 2 proceed continuation therapy . - Continuation therapy : Patients receive prednisolone vinblastine stratum 1 arm I continuation therapy . Treatment continue day 182 begin initial therapy absence disease progression unacceptable toxicity . - Arm IV : - Initial therapy : Patients receive 1-2 course prednisolone vinblastine stratum 2 arm III . - Continuation therapy : Patients receive pulse prednisolone vinblastine stratum 1 arm I continuation therapy . Treatment continue day 365 begin initial therapy absence disease progression unacceptable toxicity . - Stratum 3 ( pilot study ) ( patient multifocal bone disease and/or special site ) : - Initial therapy : Patients receive prednisolone vinblastine stratum 1 arm I initial therapy . Patients achieve NAD disease regression course 1 proceed continuation therapy . Patients disease progression receive second course* initial therapy . Patients achieve NAD disease regression course 2 proceed continuation therapy . - Continuation therapy : Patients receive pulse prednisolone vinblastine stratum 1 arm I continuation therapy . Treatment continue day 182 begin initial therapy absence disease progression unacceptable disease . NOTE : *Patients receive oral prednisolone 3 time daily day 43-45 , 50-52 , 57-59 , 64-66 , 71-73 , 78-80 second course initial therapy . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 376 patient accrue study .</detailed_description>
	<mesh_term>Histiocytosis</mesh_term>
	<mesh_term>Histiocytosis , Langerhans-Cell</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histopathologically confirm diagnosis Langerhans cell histiocytosis accord criterion define Histiocyte Society Demonstration CD1a antigenic determinant surface lesional cell ( immunocytology immunohistology ) Birbeck granules lesional cell electron microscopy Considered risk low risk accord follow criterion : Multisystem risk disease , define involvement one risk organ ( i.e. , hematopoietic system , liver , spleen , lung ) No singlesystem lung involvement Multisystem lowrisk disease Multiple organs involve without involvement risk organ Singlesystem disease Multifocal bone disease ( i.e. , lesion 2 different bone ) Localized special site involvement , CNSrisk lesions intracranial soft tissue extension vertebral lesion intraspinal soft tissue extension Vault lesion regard CNSrisk lesion PATIENT CHARACTERISTICS : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior treatment Langerhans cell histiocytosis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>childhood Langerhans cell histiocytosis</keyword>
</DOC>